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Original articleRecurrent Atypical Meningiomas: Combining Surgery and Radiosurgery in One
Effective Multimodal TreatmentAndrea Talacchi1, Francesco Muggiolu1, Antonella De Carlo1, Antonio Nicolato2, Francesca Locatelli3, Mario Meglio1-OBJECTIVE: Owing to their rarity and proteiform patho-
logic features, the clinical behavior of atypical meningi-
omas is not yet well characterized. Though the extent of
resection is believed to be a key determinant of prognosis,
limited data exist regarding optimal management of
patients with recurrent disease.
-METHODS: In this 20-year retrospective case series, we
reviewed the medical records of 46 patients with recurrent
atypical meningomas (185 lesions, 89 of which were local,
78 marginal, and 18 distant recurrences); treatment was
radiosurgery (n [ 60), surgery (n [ 56), or both (n [ 8).
The median follow-up period was 53 months. Outcome
measures were length of overall survival and disease-free
intervals and prognostic factors for survival.
-RESULTS: Overall, the median progression-free survival
was 26 months at the first recurrence and 100 months
thereafter (the sum of the later intervals). Multivariate
analysis showed that no treatment-related factors influ-
enced prognosis, whereas recurrence at the skull base
was a significant tumor-related factor limiting further
treatment. Irrespective of treatment type, the recurrence-
free interval was increasingly shorter during the clinical
course, with a higher occurrence of marginal and distant
lesions migrating to the midline and to the skull base. In
sporadic cases, disease-free intervals were longer after
wide craniotomy, tumor and dural resection with tumor-
free margin.
-CONCLUSIONS: The disease-free interval was substan-







WHO: World Health Organization
MRI: Magnetic resonance imaging
WORLD NEUROSURGERY- [-]: -- , - 2015recurrent disease in patients with atypical meningiomas.
Surgery is the mainstay for prolonging survival, while
radiosurgery can be an adjuvant strategy to gain time for
clinical observation and planning aggressive surgical
treatment.INTRODUCTIONtypical meningiomas, because of their rarity and protei-
form pathologic features, pose diagnostic and treatmentAchallenges in neuro-oncology. Their incidence is
increasing (>5%10% reported for all meningiomas) and
accounts for 20%25% of recurrent meningiomas.1,2 Definitive
cure after surgical resection is achieved in 16%18% of patients;
however, disease will recur within a few months in many cases
(62%69%).3,4 The main determinants of survival time are tumor
histology and extent of surgical resection.5-11 Unlike radiosurgery,
which has been shown to improve recurrence-free survival after
subtotal resection,9,10,12-15 studies on combined treatment have
reported inconsistent and controversial results, hindering
comparative effectiveness research. Furthermore, because the bulk
of published studies deals only with the first treatment or the first
recurrence,5,9,10,13,16 disease recurrence remains a centrally
important concern in the management of patients with atypical
meningiomas. Treatment, whatever the type, will not halt tumor
progression though it may prolong survival.
Aggressive tumor behavior is characterized by local and distant
progression. Because the modality of progression is difficult to
predict, a better understanding of the natural history of this type of
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ANDREA TALACCHI ET AL. MULTIMODAL TREATMENT FOR RECURRENT ATYPICAL MENINGIOMASThere are no studies investigating the changes in prognosis in
patients with tumor recurrence after combined treatment, namely,
why and how one or more partial responses can be achieved while
creating the conditions for effective treatment. The aim of the
present study was to assess the limitations and possibilities of
each single treatment by exploring the potential benefits of their
combination under specific conditions. To address this issue, we
describe the intermediate steps of tumor progression and growth
patterns.MATERIAL AND METHODS
Between January 1990 and December 2010, 46 patients with his-
tologically confirmed recurrent atypical meningiomas were treated
at the University Hospital of Verona. This patient subset accounts
for nearly 2.7% of all intracranial meningiomas (n ¼ 1677) treated
at our hospital. Histology was reclassified for the present study
according to the 2007 World Health Organization (WHO) classi-
fication criteria; the Ki-67 index was noted when available. First
treatment, time-to-disease recurrence, and relative treatments
received until the last follow-up visit were recorded, in addition to
clinical presentation at recurrence, pattern of recurrence, and tu-
mor site. Treatments included surgical resection and stereotactic
radiosurgery (SRS) with Leksell instrumentation. Surgical treat-
ment was classified as total (Simpson grade III) or subtotal
resection (Simpson grade IIIIV) according to postoperative
radiologic findings; SRS was characterized by the peripheral dose
intensity and target volume delivered.
The indications for type of treatment were based on radiologic
and clinical findings. Intracranial hypertension, clinical signs, and
epilepsy were more likely to require open surgery, whereas small
lesions (<2.5 cm) received SRS. Adjuvant treatment was consid-
ered when long-term benefit was anticipated and entailed surgery
followed by SRS to the same lesion(s). With this exception, each
treatment was given at disease progression and based on close
clinical and radiologic monitoring. Treatment for >1 lesion could
be performed simultaneously or not. In the latter case, the second
intervention completed the first one within an interval of a few
weeks apart. Overall, salvage treatment, often provided without
any precise synergy or specific goal, was based essentially on
physician or patient preference. Aggressive surgical treatment,
large craniotomy, and extensive dural resection around the tumor
was seldom performed. As a rule, it was not determined by disease
progression per se but rather by pretreatment planning.
Disease-free interval was defined as the period between treat-
ment and disease progression event, as documented by magnetic
resonance imaging (MRI), and served as the end point for
measuring the treatment effect. Recurrence was defined as a
disease progression event as documented by follow-up MRI
findings (36 months). During tumor progression, salient char-
acteristics of recurrent lesions were recorded, including histology,
laterality, pattern of failure, number of lesions, number, and site
of recurrences.
Based on tumor characteristics and the goal of treatment, which
is ideally to control the disease rather than the single lesion, the
pattern of failure was classified as local, marginal, or distant.
Local failure was defined as tumor regrowth within the field of
previous treatment, taking as reference the craniotomy and2 www.SCIENCEDIRECT.com WORLD NEUeffective marginal radiation dose; marginal failure was defined as
tumor regrowth at the resection margin and within 2 cm of the
aforementioned limits; and distant failure was defined as the
occurrence of a new lesion distant (>2 cm) from any other lesion.
This means that during the clinical course, marginal recurrences
might lead to lesions that are distant from the original field.
Furthermore, tumor behavior may potentially involve multiple foci
in the perimeter of any lesion, resulting in devastating spread of
disease.
Disease and treatment-related variables were entered into the
prognostic analysis to identify the determinants of survival in 2
different Cox regression models: 1 included tumor side, histology,
site, and type of recurrence; the other included tumor side, his-
tology, first treatment, and type of subsequent treatments.
RESULTS
The study sample was 46 patients operated on for recurrent me-
ningiomas (23 men and 23 women; age range 2873 years). The
mean clinical history was 6.3 months (range 160 months, me-
dian 3 months); diagnosis was based on symptoms and clinical
signs. All cases presented a single mass (mean tumor size 5.1 cm,
range 2.87.6 cm) on radiology. The mass was on the right side in
25 cases and on the left side in 21; the prevalent site was located
along the midline (falx cerebri and parasagittal in 17% and 26% of
cases, respectively). Sixteen (35%) were WHO grade I meningi-
omas at the first treatment. Total surgical resection was performed
in 72% of cases and subtotal resection in 28% (Table 1).
First Recurrence of Disease
First recurrence occurred at 26 months (median), 66 months after
total resection and 22 months after subtotal resection, demon-
strating a significant efficacy of the extent of removal (P < 0.01)
(Figure 1). Recurrence was local in 31 cases (62%), marginal in 17
(34%), and distant in 2 (4%). Multiple lesions were detected in 9
cases (19%).
Tumor Growth Pattern Following Treatment and Survival
Following the first recurrence, 3.6 subsequent recurrences per
patient on average were noted (range 17), with a mean time to
overall survival of 100 months (interquartile range 72144).
Symptomatic presentation was rare (18%) as compared with
radiologic evidence of tumor regrowth. At the time of the last
follow-up examination (median 52 months, range 33146), 89 of
the 185 lesions were local recurrences, 78 marginal, and 18 distant
and had been treated with SRS in 60 cases, surgery in 56, and both
treatments in 8. Five (11%) patients presented with 1 lesion, and 41
(89%) with multiple lesions, 22 of which were bilateral (48%). The
tumor harbored atypical features at the second recurrence in only 1
patient and showed malignant transformation at the end of the
clinical course in 10 patients (21%). Thirty-three patients were
alive (72%), and 13 (28%) had died at the time of the last
follow-up.
Determining which future strategy to choose case-by-case ulti-
mately relies on knowledge of the disease growth pattern. Given
this multifaceted picture, we describe the factors associated with
time-to-disease intervals between recurrences and discuss the
treatment modalities and strategies in relation to tumor behavior.ROSURGERY, http://dx.doi.org/10.1016/j.wneu.2015.10.013
Table 1. Characteristics of Patients, Tumors, and Treatment







Tumor side at onset
Left 21 45.6
Right 25 54.4
Tumor location at onset
Convexity 16 34.7
Parasagittal 12 26.1
Skull base 10 21.7
Falx 8 17.4
Presenting symptom at onset
Seizures 12 26.0
Intracranial hypertension 10 21.7
Unilateral hyposthenia 6 13.0
Cognitive deterioration 3 6.5
Others 15
Neurologic signs at onset
Hemiparesis 9 19.5

















Characteristic Number of patients %
Surgery
<3 Recurrences 38/56 67.8





<3 Recurrences 35/60 58.4
3 Recurrences 25/60 41.6
Radiation dose delivered
12 Gy 28/60 46.7
>12 Gy 32/60 53.3
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ANDREA TALACCHI ET AL. MULTIMODAL TREATMENT FOR RECURRENT ATYPICAL MENINGIOMASGrowth Pattern. The tumor growth pattern changed during the
clinical course. The prevalent pattern at the first recurrence was
local, becoming marginal at the second and third recurrence and
distant at the fourth and fifth recurrence (Figure 2A). This pattern
of progression suggests that early aggressive treatment may be
more effective than repeated salvage treatments. The tumor
location changed during the clinical course. Most lesions
migrated to the midline, with fewer in the convexity or the skull
base (Figure 2B). This latter result is probably biased by the fact
that large, recurrent skull-base tumors are not amenable to
treatment. Evaluation of the direction of tumor progression can
prevent unmanageable situations and help in planning radical
surgery. In tumor invasion of the superior sagittal sinus, for
example, the right time for sinus resection is problematic: if the
tumor is resected before it occludes the superior sagittal sinus,
venous engorgement may occur; if it is removed after the superior
sagittal sinus has been invaded, the tumor may have already
spread. The effect of tumor behavior on survival was demonstrated
by the adjusted Cox regression model. Among the disease-related
factors examined, skull base location was the only one signifi-
cantly associated with shorter survival times (P ¼ 0.01) (Table 2).
Treatment. The overall survival in recurrent cases was 100 months,
and the progression-free survival rate at 5 years was 30% after total
resection and 11% after subtotal resection. Differently from the
initial treatment, when progression-free survival depended on the
extent of resection, the subsequent disease-free intervals were
increasingly shorter independent of treatment type (SRS vs. sur-
gery) and modality (extent of resection and radiation dose)
(Figure 2C; see Table 1). The general rule is that the higher the
number of recurrences, the shorter the disease-free interval
regardless of treatment. This was confirmed on prognostic anal-
ysis, which showed that treatment-related factors were not asso-
ciated with survival nor that adjuvant treatment (n ¼ 16www.WORLDNEUROSURGERY.org 3
Figure 1. First recurrence-free survival (dashed line) and overall survival




































































Figure 2. (A) Changes in recurrence type during the clinical course; (B)
changes in tumor location during the clinical course; and (C) changes in
the length of disease-free intervals during the clinical course.
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ANDREA TALACCHI ET AL. MULTIMODAL TREATMENT FOR RECURRENT ATYPICAL MENINGIOMASprocedures) performed in 8 patients (17%) prolonged disease-free
survival (16 months) (see Table 2). But this is an apparent finding
because the efficacy improved by changing the treatment
approach, being more aggressive and aiming at Simpson grade
0, as was seen in sporadic cases (see Case 2).
Exemplificative Cases
Case 1. A 58-year-old woman had a history of generalized epileptic
seizures. MRI showed a right parasagittal meningioma infiltrating
the anterior and middle third of the superior sagittal sinus.
Simpson grade III resection was performed in March 2007. The
patient was followed up with periodic MRI. The first recurrence
(1 local and 1 posterior marginal lesion) occurred 18 months later.
In March 2009, SRS was performed on the posterior marginal
lesion (14 Gy); 8 months later, in November 2009, surgical
resection was performed because of local recurrence with pro-
gression. In January 2011, another operation was performed to
remove the lesion, which had previously been treated with SRS,
again limiting the target to the growing lesion. Eight months later,
there was evidence of dural and falcine infiltration without tumor
mass. In March 2012, a new recurrence occurred and palliative SRS
was performed (11 Gy). No further treatment was administered 8
months later when MRI showed a large contralateral parasagittal
meningioma. Tumor histology remained unchanged since the first
procedure (Figure 3).
Comment: 6 years of survival; disease-free intervals: first
recurrence at 18 months postoperative; 4 further treatments (2
operations and 2 SRS), 1 for each new lesion, with disease-free
periods shorter or similar in duration to that after the first
treatment.
Case 2. A 64-year-old woman had a 3-month history of recurrent
motor epileptic seizures affecting the left side of her body. MRI
showed a right parasagittal meningioma infiltrating the middle
third of the superior sagittal sinus. The sinus was not occluded by
the tumor; some remnants were left inside at the first operation
(April 2004). Local regrowth was treated with SRS (12 Gy) in
January 2006. MRI studies were obtained every 6 months there-
after. In May 2008, 13 months after the initial finding of4 www.SCIENCEDIRECT.com WORLD NEUrecurrence, surgery was performed to remove a local lesion
occluding the superior sagittal sinus and a marginal lesion of the
falx. In January 2010 and March 2011, three lesions (1 local, 2
marginal) close to the superior sagittal sinus were treated with
SRS (10 Gy and 12 Gy, respectively). The patient was carefully
monitored for evidence of new tumor growth. In April 2012 she
was reoperated with the intention to remove the tumor completely
with free dural margins. At the last follow-up examination the
patient is still tumor free. Histology remained unchanged since
the first procedure (see Figure 3).
Comment: 10 years of survival and still alive; disease-free in-
terval: first recurrence at 21 months postoperative; 4 further
treatments (2 operations and 2 SRS) for 8 lesions, with disease-
free periods shorter or similar in duration to that after the first
treatment, except for 1 Simpson grade 0 resection followed by a
32-month disease-free period, and still disease free.
Case 3. A 71-year-old woman had a 1-month history of progressive
headache. MRI showed a left frontal hyperostotic meningioma. In
October 2009 surgery was performed to remove the tumor, bone,ROSURGERY, http://dx.doi.org/10.1016/j.wneu.2015.10.013
Table 2. Hazard Ratio (HR with 95% Confidence Intervals [CI] and P Value) of Death from Recurrent Meningioma in the 46 Patients
Controlling for Tumor and Treatment Variables
Tumor Treatment
HR 95% CI P value HR 95% CI P value
Side 0.44 0.17-1.15 0.10 Side 2.25 0.49-10.25 0.29
Histology 1.26 0.38-4.22 0.71 1-treatm 0.55 0.18-1.64 0.28
Recurr base 0.24 0.08-0.75 0.01 Histology 0.98 0.29-3.32 0.97
Recurr sss 0.33 0.10-1.10 0.07 Surgery 0.19 0.02-1.93 0.16
SRS 1.68 1.65-17.13 0.66
Side, left, right; histology, atypical on new tumor, atypical on recurrence; 1-treatm, total removal, subtotal removal; recurr base, skull base as final site of recurrence; recurr sss, superior sagittal
sinus as final site of recurrence; surgery, cases with surgery as prevalent treatment on recurrences; SRS, cases with SRS as prevalent treatment on recurrences.
Figure 3. Exemplifying different strategies in similar tumors. Case 1: a strategy leading to failure (sagittal magnetic resonance [MR] images). (A) First
recurrence with 2 marginal lesions; the anterior lesion underwent surgery, the posterior lesion stereotactic radiosurgery (SRS) and then surgery. (B) A new
recurrence developed from the infiltrated dura 8 months after Simpson grade II resection and received SRS. (C) New and last recurrence 8 months later (patient
refused operation). Case 2: a successful strategy (sagittal MR images). (A) First local recurrence received SRS. (B) New recurrences grew slowly despite
repeated SRS; aggressive surgery was planned. (C) Postoperative image.
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ANDREA TALACCHI ET AL. MULTIMODAL TREATMENT FOR RECURRENT ATYPICAL MENINGIOMASand dura, followed by cranioplasty and duraplasty during the same
operation. MRI scans obtained in April 2010 were negative. A local
lesion appeared in September. Progression was noted in
December, at which time the patient was reoperated. MRI scans
obtained in February 2011 were negative. Two lesions appeared at
the margins of the craniotomy in June; SRS to the growing lesions
was performed (14 Gy each) in September. At that time, 1 of the 2
lesions had reached the skull base and was judged inoperable at
progression (Figure 4). The patient died in February 2012 due to
intracranial hypertension. Histology remained unchanged since
the first procedure (Ki-67 index 9%).
Comment: 28 months of survival; disease-free interval: first
recurrence at 11 months postoperative; 2 further treatments (1
operation and 1 SRS) for 3 new lesions, with disease-free periods
shorter or similar in duration to that after the first treatment.
Rapid progression was probably due to higher tumor
malignancy.DISCUSSION
Atypical meningiomas pose diagnostic and treatment challenges
because of the many potential determinants for prognosis. We
investigated the clinical course from the first recurrence onward
and report findings that could aid in decision making. In this
retrospective series, midline meningiomas were the prevalent
location at presentation and increased in occurrence with subse-
quent recurrences. This prevalence is different from other authors
who reported a tumor distribution comparable with benign
counterparts but similar with the recurrence sites Cao et al. re-
ported.3,9,12,17 Prevalence on the midline may be due to either
dysembryogenetic defects during closing of the neural crest or an
acquired mutation, but it does not seem to be linked to a higher
rate of subtotal resection.6 Kane et al. proposed an embryologic
origin of the skull base dura different from the convexity dura to
explain why nonskull base locations are a prognostic factor for
the development of atypical meningiomas.18Figure 4. Exemplifying an aggressive case. Case 3: (A) First recurrence 11 month
repeated Simpson I removal, on axial (B) and coronal (C) planes. The tumor has r
6 www.SCIENCEDIRECT.com WORLD NEUWhatever the cause, the tumor originates as an isolated mass
and regrows as multiple lesions stemming from the margin of the
previous lesions (with or without residual mass), often distant
from one another and sometimes unconnected with the previous
lesions in the final stages. A variable but high number of cases
(14%57%) become atypical on the second operation after inad-
equate extent of resection of the first tumor.12,19
Multicentricity varies from 19% at the first recurrence to 89% at
the last follow-up, and marginal recurrence is progressively higher
than the local type at the second and third recurrence, rendering
management increasingly difficult.10 Therefore local control is an
erroneous outcome measure because it provides no effective
indications about the state of the disease. As the disease may be
local, marginal, or distant with respect to the previous
localization, a preferable indicator of treatment efficacy is
disease-free interval.20-23
Multiple lesions are clinically difficult to manage because of
refractoriness to treatment (total and subtotal surgical resection,
high- or low-dose intensity SRS) and disease progression, with
ever shorter disease-free intervals during the clinical course
regardless of treatment type.12 The findings from this retrospective
analysis challenge assumptions about treatment. As regards
surgery, the definition of Simpson grade III (total resection)
should be revised in light of mounting criticism that even
Simpson grade I might not be a reliable gold standard for this
particular type of tumor.19,24,25 As regards radiotherapy, SRS
seems to be as efficacious as fractionated radiotherapy and it is
associated with fewer side effects: depending on peripheral dose
intensity, tumor volume, and timing, it can delay tumor
regrowth.13,21,26,27
We also found a considerable length of overall survival (100
months) after first recurrence at the cost of multiple interventions
(34 per patient on average), each covering 1 or more le-
sions.11,28,29 The time to first relapse in our series compares
favorably with the published data (2043 months).30 There is
some evidence that later performance is worse; unfortunately,
however, studies do not report further details about survivals after Simpson I removal; second and last recurrence 9 months after
eached the skull base and infiltrated the orbit.
ROSURGERY, http://dx.doi.org/10.1016/j.wneu.2015.10.013
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ANDREA TALACCHI ET AL. MULTIMODAL TREATMENT FOR RECURRENT ATYPICAL MENINGIOMAStime.12,13,16,19,21,29,31 In our series, the mean disease-free survival
time for each subsequent recurrence was 24 months (similar to the
first recurrence), but it decreased with each recurrence, ranging
from 3235 months after treatment for the first recurrence to
610 months after the fourth or fifth recurrence. This can be
explained by evidence showing that molecular and behavior pro-
gression toward an aggressive clinical course is more rapid in
atypical than benign meningiomas.6,19,29,32 In a minority of our
cases, however, the clinical course was shorter after the first
recurrence because of high tumor cell proliferation, without a
significant correlation with Ki-67, which remains a controversial
marker of tumor aggressiveness.3,33
The dysembryogenetic mechanism does not contrast with the
notion of a treatment-driven mechanism such as stepwise tumor
progression, according to which subtotal resection and selection
of radioresistant cells may stimulate tumor progression.4,22
Simpson grade IIIIV, as well as stable disease after SRS, is a
provisory result because viable tumor cells capable of migration
and replication make the disease even worse at each new recur-
rence. Nonetheless, SRS may slow regrowth while new lesions
may develop, for which a larger craniotomy can be planned to treat
old and new lesions during the same session. Sharing Borovich
et al.’s observation of tumor nests within the dura some centi-
meters around the mass, we suggest giving priority to tumor
resection where a dural-free margin is resectable and to tumors
with mass effect or being symptomatic, at the second or third
recurrence, but possibly not later.24,25 In the absence of any
preferential treatment, this strategy holds promise to achieve
better results and prolong disease-free intervals.
Moreover, arguments claiming that large craniotomy and parallel
dural resection are trivial technical issues in brain tumor surgery or
meningioma treatment are akin to the questionable belief that
minimal invasive surgery is synonymous with safety. On the con-
trary, the choice of surgical technique is vitally important in treating
benign tumors, should be adapted to the disease, and should obtain
a definitive cure for the disease. This holds true particularly in light
of evidence that many atypical meningiomas (30%35%)3 originate
from recurrent grade I meningiomas, which, we might add, often
start from the margin of dural resection.4 In addition, second orWORLD NEUROSURGERY- [-]: -- , - 2015further surgery for tumor recurrence is no more burdened by
complications than primary surgery.34
Importantly, the skull base and midline are inevitable sites of
tumor migration, and skull base represents the only single nega-
tive prognostic factors for survival. Because this is a potential
limiting factor for treatment, every effort should be undertaken
before the tumor reaches the skull base or the tentorium.7,28 At
every recurrence, choice and timing of treatment remain crucial
and can only be addressed by careful consultation between the
radiation therapist and the neurosurgeon. Although standard
treatment (SRS and Simpson I removal) have failed per se to
prolong progression-free survival, repeat treatment prolonged
overall survival in our series, in which single cases provided
further insights and hope for a designing a successful strategy.
This study is subject to the normal biases of a retrospective
review, especially the potential selection bias of the cohorts.
Because of the relatively rare incidence of atypical meningiomas
and their variety, a broad inclusion criterion was necessary, with
the drawback that data analysis was limited by the small number
of patients.
CONCLUSIONS
Multicentricity is an essential aspect of tumor progression. Mar-
ginal regrowth is the most frequent pattern of recurrence and of
unpredictable direction in early recurrences. Skull base recurrence
after initial treatment is a significant negative prognostic factor for
survival. These features are key to tailoring treatment on a case-by-
case basis. Total surgical resection in recurrences is not as effec-
tive as it is the first time, and progression-free intervals are shorter
with each later recurrence and treatment, regardless of the treat-
ment type (surgery or SRS). Stereotactic radiosurgery, as part of
palliative care in recurrences, should be delivered to delay and
optimize surgical treatment. Timing is critical for appropriate
aggressive surgery to obtain tumor resection and extended dural
detachment with wide craniotomy.
For the majority of patients, overall survival after recurrence may
be less hopeless than previously reported if care is pursued with
perseveration by neurosurgeons and radiotherapists working
together to decide how and when to perform aggressive surgery.REFERENCES
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